Inclisran

September 2, 2019 ORION-11: A Landmark Event for RNAi Therapeutics The results from the ORION-11 Phase 3 study of inclisiran, presented earlier today at the European Society of Cardiology meeting represent a landmark event... Read More ›

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site

FOLLOW US